2026-01-27 - Analysis Report
**Company Overview**
Thermo Fisher Scientific is a multinational biotechnology company that specializes in the development and manufacture of instruments, reagents, and consumables for scientific research, routine testing in laboratories, diagnostics, and applied markets.

**Return Rate Comparison**

- TMO return rate (rate): 110.26%
- S&P 500 (VOO) return rate (rate_vs): 127.58%
- Divergence: -16.40 (max: 111.30, min: -73.00, relative divergence: 30.70%)

The cumulative return of TMO is lower than the S&P 500, indicating a possible underperformance of the stock. However, the divergence is relatively low compared to its maximum and minimum values.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 30.0% | 17.2% | 21.0% | 1.1 | 84.1B |
| 2017-2019  | 67.0% | 17.2% | 42.0% | 1.1 | 122.1B |
| 2018-2020  | 80.0% | 23.7% | 56.0% | 0.8 | 175.0B |
| 2019-2021  | 144.0% | 23.7% | 80.0% | 0.8 | 250.7B |
| 2020-2022  | 50.0% | 23.7% | 45.0% | 0.8 | 206.9B |
| 2021-2023  | -48.0% | 26.2% | -66.0% | 0.9 | 199.4B |
| 2022-2024  | -66.0% | 24.5% | -95.0% | 0.9 | 195.4B |
| 2023-2025  | -29.0% | 34.3% | -104.0% | 0.8 | 217.7B |

The CAGR and Alpha values show significant variability across different years, indicating possible changes in the stock's performance. The Beta value also shows some fluctuations, but remains relatively close to the mean.

**Recent Stock Price Fluctuations**

- Close: $626.62
- Last-market: $626.62 (price change: 0.1%)
- 5-day SMA: $629.47
- 20-day SMA: $611.54
- 60-day SMA: $587.12

The stock is currently trading very close to its 5-day SMA, but slightly below its 20-day and 60-day SMAs.

**RSI, PPO Index Analysis**

- Market Risk Indicator (MRI): 0.70
- RSI: 57.26
- PPO: 0.11
- Hybrid Signal: Buy (Cash 0%)
- Risk Level: Medium
- Recent (20 days) relative divergence change: 0.70 (+)
- 7-day Rank change: 15 (+)
- 7-day Dynamic Expected Return change: 87.20 (+)
- Expected Return (%): 43.30%

The RSI value is slightly lower than 50, indicating possible oversold conditions. However, the PPO value is negative, indicating potential bearish momentum. The market risk indicator suggests a moderate risk level.

**Recent News & Significant Events**

* [2026-01-24] Thermo Fisher Scientific Inc. $TMO Stock Position Raised by Mn Services Vermogensbeheer B.V. - MarketBeat
* [2026-01-26] Thermo Fisher Scientific stock rises toward $631 as TMO heads into Jan. 29 earnings - TechStock²
* [2025-12-31] Here’s What Lifted Thermo Fisher Scientific (TMO) in Q3 - Yahoo Finance
* [2026-01-12] How Thermo Fisher and NVIDIA want to turn routine labs into AI powerhouses - Stock Titan
* [2026-01-12] Thermo Fisher Chief Operating Officer Michel Lagarde Leaving Company - The Wall Street Journal
* [2026-01-22] Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth - Nasdaq

These recent events suggest a positive outlook for the company, with expectations of earnings growth.

**Analyst Opinions**

Analyst Consensus:
* Key: Buy
* Mean (1=StrongBuy~5=Sell): 1.54 (~Buy)
* Opinions: 23
* Target Price (avg/high/low): 652.61 / 750.00 / 575.00

The consensus among analysts suggests a buy recommendation, with a mean rating of 1.54.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-31 | 4.28 | 11.12 B$ |
| 2025-08-01 | 4.28 | 10.86 B$ |
| 2025-05-02 | 3.99 | 10.36 B$ |
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2025-10-31 | 4.26 | 10.60 B$ |

The earnings per share (EPS) and revenue values show stability across different quarters.

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $11.12B | 41.21% |
| 2025-06-30 | $10.85B | 40.61% |
| 2025-03-31 | $10.36B | 40.86% |
| 2024-12-31 | $11.39B | 42.32% |
| 2024-09-30 | $10.60B | 40.84% |

The profit margin values show some fluctuations across different quarters, but remain relatively stable.

**Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.02B | 3.17% |
| 2025-06-30 | $50.51B | 3.20% |
| 2025-03-31 | $49.39B | 3.05% |
| 2024-12-31 | $49.59B | 3.69% |
| 2024-09-30 | $48.99B | 3.33% |

The equity values show a slight decrease across different quarters, while the return on equity (ROE) values show some fluctuations.

**Comprehensive Analysis**

The analysis suggests a relatively stable stock with a possible positive outlook. The divergence in cumulative return rate is relatively low, indicating a possible underperformance compared to the S&P 500. However, the RSI value is slightly lower than 50, indicating possible oversold conditions. The market risk indicator suggests a moderate risk level. The analyst consensus suggests a buy recommendation, and the recent news and significant events suggest a positive outlook for the company. However, the recent stock price fluctuations suggest a possible correction in the near term.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.